Biofourmis-a fast-growing global leader in digital therapeutics that powers personalized predictive care-discovers, develops and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and complement pharmacotherapy, and cost-effective solutions for payers. Biofourmis has built Biovitals®, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics product pipeline across multiple therapeutic areas-including heart failure, oncology, infectious disease (i.e., COVID-19), chronic pain, acute coronary syndrome and COPD.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/03/20 | $100,000,000 | Series C |
EDB Investments MassMutual Ventures Openspace Ventures SoftBank Vision Fund 2  | undisclosed |
| 04/26/22 | $300,000,000 | Series D |
CVS Health Ventures General Atlantic | undisclosed |
